Paperpal Prime Logo

Cancer Chemotherapy and Pharmacology : Impact Factor & More

eISSN: 1432-0843pISSN: 0344-5704

Aims and Scope of Cancer Chemotherapy and Pharmacology

Cancer Chemotherapy and Pharmacology is a peer-reviewed medical journal covering oncological pharmacotherapy. It was established in 1978 and is published by Springer Science+Business Media. The editors-in-chief are E.Chatelut (Paul Sabatier University) and E.A. Sausville (University of Maryland). It has been included in Index medicus (MEDLINE) since its first issue. According to the ISI 2016 Journal Citation Reports, the journal has an impact factor of 2.737, and its ranking was 98/254 (Pharmacology & Pharmacy) and 122/217 (Oncology). Less

Key Metrics

CiteScore
5.9
Impact Factor
< 5
SJR
Q2Oncology
SNIP
0.96
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Cancer Chemotherapy and Pharmacology

Cancer Chemotherapy and Pharmacology Journal Specifications

Overview
Publisher SPRINGER
Language English
Frequency Monthly
General Details
LanguageEnglish
FrequencyMonthly
Publication Start Year1978
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in Cancer Chemotherapy and Pharmacology ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Cancer Chemotherapy and Pharmacology

Ferroptosis suppression by MYC confers oxaliplatin resistance in colorectal cancer via FTH1 and GPX4.
  • 6 Aug 2026
  • Cancer chemotherapy and pharmacology
Drug repurposing as a promising therapeutic strategy against renal cell carcinoma.
  • 21 Jul 2026
  • Cancer chemotherapy and pharmacology
Zolbetuximab-induced gastric mucosal injury and hypoalbuminemia: a mechanism-informed clinical analysis.
  • 20 Jul 2026
  • Cancer chemotherapy and pharmacology
Red blood cell partitioning and the interpretation of palbociclib plasma concentrations - a letter to the editor.
  • 20 Jul 2026
  • Cancer chemotherapy and pharmacology
Correction to: The CetuxIMAX study: a population pharmacokinetic approach to modelling the pharmacokinetics and pharmacodynamics relationships of Cetuximab in patients with head and neck cancer.
  • 18 Jul 2026
  • Cancer chemotherapy and pharmacology
Design characteristics of mass balance studies conducted for protein kinase inhibitors.
  • 13 Jul 2026
  • Cancer chemotherapy and pharmacology
Ferroptosis suppression by MYC confers oxaliplatin resistance in colorectal cancer via FTH1 and GPX4.
  • 6 Aug 2026
  • Cancer chemotherapy and pharmacology
Drug repurposing as a promising therapeutic strategy against renal cell carcinoma.
  • 21 Jul 2026
  • Cancer chemotherapy and pharmacology
Zolbetuximab-induced gastric mucosal injury and hypoalbuminemia: a mechanism-informed clinical analysis.
  • 20 Jul 2026
  • Cancer chemotherapy and pharmacology
Red blood cell partitioning and the interpretation of palbociclib plasma concentrations - a letter to the editor.
  • 20 Jul 2026
  • Cancer chemotherapy and pharmacology
Correction to: The CetuxIMAX study: a population pharmacokinetic approach to modelling the pharmacokinetics and pharmacodynamics relationships of Cetuximab in patients with head and neck cancer.
  • 18 Jul 2026
  • Cancer chemotherapy and pharmacology
Design characteristics of mass balance studies conducted for protein kinase inhibitors.
  • 13 Jul 2026
  • Cancer chemotherapy and pharmacology

FAQs on Cancer Chemotherapy and Pharmacology